eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Management of bleeding

  • As with other anticoagulants, patients taking ELIQUIS are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. ELIQUIS administration should be discontinued if severe haemorrhage occurs.
  • Although treatment with ELIQUIS does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of ELIQUIS exposure may help to inform clinical decisions, e.g. overdose and emergency surgery.
  • An agent to reverse the anti-factor Xa activity of apixaban is available. This agent is called andexanet alfa, please refer to its Summary of Product Characteristics for more information (available on the European Medicines Agency website).

ELIQUIS is approved for a broad range of indications1

The approved indications for ELIQUIS are based on a robust clinical trial programme1

Access further resources, including videos, patient materials and downloadable supporting materials

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NSAID = Non-Steroidal Anti-Inflammatory Drug   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SNRI = Serotonin Norepinephrine Reuptake Inhibitor   
SSRI = Selective Serotonin Reuptake Inhibitor


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.